Cargando…

Challenges and advances in the assessment of the disposition of antibody‐drug conjugates

Antibody‐drug conjugates (ADCs) are a rapidly growing therapeutic platform for the treatment of cancer. ADCs consist of a cytotoxic small molecule drug linked to an antibody to provide targeted delivery of the cytotoxic agent to the tumor. Understanding the pharmacokinetics (PK) and pharmacodynamics...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kamath, Amrita V., Iyer, Suhasini
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2015
Materias:	Invited Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5032988/ https://www.ncbi.nlm.nih.gov/pubmed/25904406 http://dx.doi.org/10.1002/bdd.1957

Ejemplares similares

Preclinical Pharmacokinetic Considerations for the Development of Antibody Drug Conjugates
por: Kamath, Amrita V., et al.
Publicado: (2014)

Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer Therapeutics
por: Kim, Eunhee G., et al.
Publicado: (2015)

Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients
por: Lucas, Andrew T., et al.
Publicado: (2019)

Antibody Format and Serum Disposition Govern Ocular Pharmacokinetics of Intravenously Administered Protein Therapeutics
por: Shivva, Vittal, et al.
Publicado: (2021)

Antibody-Drug Conjugates: Possibilities and Challenges
por: Nejadmoghaddam, Mohammad-Reza, et al.
Publicado: (2019)

Antibody-drug conjugates: recent advances in conjugation and linker chemistries
por: Tsuchikama, Kyoji, et al.
Publicado: (2016)

Advances and Limitations of Antibody Drug Conjugates for Cancer
por: Mckertish, Candice Maria, et al.
Publicado: (2021)

Antibody–drug conjugates: Recent advances in payloads
por: Wang, Zhijia, et al.
Publicado: (2023)

Targeting cancer with antibody-drug conjugates: Promises and challenges
por: Dean, Alexis Q., et al.
Publicado: (2021)

Drug Conjugates Such as Antibody Drug Conjugates (ADCs), Immunotoxins and Immunoliposomes Challenge Daily Clinical Practice
por: Janthur, Wolf-Dieter, et al.
Publicado: (2012)

Challenges and advances in optical 3D mesoscale imaging
por: Munck, Sebastian, et al.
Publicado: (2022)

Advancing drug discovery using the power of the human genome
por: Heilbron, Karl, et al.
Publicado: (2021)

Recent advances of antibody drug conjugates for clinical applications
por: Zhao, Pengxuan, et al.
Publicado: (2020)

Antibody–drug conjugates: Recent advances in linker chemistry
por: Su, Zheng, et al.
Publicado: (2021)

Advancing antibody-drug conjugates in gynecological malignancies: myth or reality?
por: Nerone, Marta, et al.
Publicado: (2022)

Advances in Targeted Therapy of Breast Cancer with Antibody-Drug Conjugate
por: Subhan, Md Abdus, et al.
Publicado: (2023)

Research in pediatric cardiac anesthesia and intensive care in low- and middle- income countries and low resource settings: Challenges and opportunities
por: Iyer, Parvathi U, et al.
Publicado: (2021)

Antibody-Oligonucleotide Conjugates: A Twist to Antibody-Drug Conjugates
por: Dugal-Tessier, Julien, et al.
Publicado: (2021)

Challenges in Optimising the Successful Construction of Antibody Drug Conjugates in Cancer Therapy
por: Mehrling, Thomas, et al.
Publicado: (2018)

Unraveling the complexity of therapeutic drug monitoring for monoclonal antibody therapies to individualize dose in oncology
por: Chatelut, Etienne, et al.
Publicado: (2021)

Sex Differences in Drug Disposition
por: Soldin, Offie P., et al.
Publicado: (2011)

Antibody-drug conjugates for the treatment of lymphoma: clinical advances and latest progress
por: Chu, Yurou, et al.
Publicado: (2021)

Targeting BCMA in Multiple Myeloma: Advances in Antibody-Drug Conjugate Therapy
por: Xing, Lijie, et al.
Publicado: (2023)

Introduction to Antibody-Drug Conjugates
por: Pettinato, Mark C.
Publicado: (2021)

Advancing Pediatric Antibacterial Drug Development: A Critical Need to Reinvent our Approach
por: Noel, Gary J, et al.
Publicado: (2018)

Prediction of Human Pharmacokinetics of Antibody–Drug Conjugates From Nonclinical Data
por: Li, Chunze, et al.
Publicado: (2019)

Recent advances in spatially resolved transcriptomics: challenges and opportunities
por: Lee, Jongwon, et al.
Publicado: (2022)

Understanding Inter-Individual Variability in Monoclonal Antibody Disposition
por: Thomas, Veena A., et al.
Publicado: (2019)

Advances in Antibody-Drug Conjugates in the Treatment of HER2-Positive Breast Cancer
por: Yu, Yongchao, et al.
Publicado: (2022)

Novel development strategies and challenges for anti-Her2 antibody-drug conjugates
por: Zhang, Xinling, et al.
Publicado: (2022)

Challenges and opportunities to develop enediyne natural products as payloads for antibody-drug conjugates
por: Adhikari, Ajeeth, et al.
Publicado: (2021)

ADME Considerations and Bioanalytical Strategies for Pharmacokinetic Assessments of Antibody-Drug Conjugates
por: Mou, Si, et al.
Publicado: (2018)

Racial Disparity in Drug Disposition in the Digestive Tract
por: Gao, Song, et al.
Publicado: (2021)

Her-2 Targeted Therapy in Advanced Urothelial Cancer: From Monoclonal Antibodies to Antibody-Drug Conjugates
por: Albarrán, Víctor, et al.
Publicado: (2022)

Antibody-Drug Conjugates in Bladder Cancer
por: Vlachostergios, Panagiotis J., et al.
Publicado: (2018)

Acquired Resistance to Antibody-Drug Conjugates
por: Collins, Denis M., et al.
Publicado: (2019)

Antibody–Drug Conjugates for Cancer Therapy
por: Parslow, Adam C., et al.
Publicado: (2016)

Antibody–Drug Conjugates: The Last Decade
por: Joubert, Nicolas, et al.
Publicado: (2020)

Antibody–Drug Conjugates for Cancer Therapy
por: Hafeez, Umbreen, et al.
Publicado: (2020)

Clinical Pharmacology of Antibody-Drug Conjugates
por: Mahmood, Iftekhar
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_m58j9k89spkbi7ql36ak2hq1q7